---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-023332"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T12:12:52.936947+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Insmed unveils four new research platforms; targets 6 INDs by 2025; DMD gene therapy trial in 2023

## Summary
- Gene therapy with targeted AAV delivery; DMD clinical trial to start 2023, muscle biopsy data expected H1 2024.
- RNA end-joining (REJ) technology targets Stargardt disease; IND submission expected by end of 2024.
- Protein deimmunization platform (DbD) using AI to enable redosable gene therapy and therapeutic proteins.
- Proprietary algae-based manufacturing platform for AAV capsid production; $500K investment from CureDuchenne Ventures.
- Expects at least six IND applications across platforms by end of 2025.

## SEC filing metadata
- accession: 0001140361-23-023332
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036123023332/0001140361-23-023332-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036123023332/brhc20052589_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-023332
- JSON: https://secwatch.observer/filing/0001140361-23-023332.json
- Plain text: https://secwatch.observer/filing/0001140361-23-023332.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.